"Samuel F. Hunter, MD, PhD, is a neurologist and neuroimaging specialist based in Franklin, TN. An internationally renowned expert in multiple sclerosis & demyelinating diseases, Dr. Hunter has over 27 years of experience specializing in diagnoses and treatment of diseases including impaired function of the brain, spinal cord, peripheral nerves, muscles, autonomic nervous system, and blood vessels relating to these structures. Advanced Neurosciences Institute is a regional neurological treatment center serving patients throughout the Southeastern United States established in 1997. It is Tennessee’s first subspecialty trained facility focused on MS. ANI provides advanced imaging, diagnostic services, & medical research technology."

During the past decade, Advanced Neurosciences Institute conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 6 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Advanced Neurosciences Institute" #1 sponsor was "Genzyme, a Sanofi Company" with 3 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Novartis" with 2 trials sponsored, "Acorda Therapeutics" with 1 trials sponsored and "Actelion" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Advanced Neurosciences Institute" #1 collaborator was "Bayer" with 3 trials as a collaborator, "Immune Tolerance Network (ITN)" with 1 trials as a collaborator and "Novel Pharmaceutics Institute" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Advanced Neurosciences Institute" are "Multiple Sclerosis" (11 trials), "Multiple Sclerosis, Relapsing-Remitting" (4 trials), "Central Neuropathic Pain" (1 trials), "Hypogammaglobulinemia" (1 trials) and "Immunodeficiency" (1 trials). Many other conditions were trialed in "Advanced Neurosciences Institute" in a lesser frequency.

Most popular intervention types in "Advanced Neurosciences Institute" are "Drug" (13 trials), "Biological" (4 trials), "Other" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Interferon beta-1a" (3 trials), "Ocrelizumab" (3 trials), "Alemtuzumab" (2 trials) and "ANK-700" (1 trials). Other intervention names were less common.

The vast majority of trials in "Advanced Neurosciences Institute" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Advanced Neurosciences Institute". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Advanced Neurosciences Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Advanced Neurosciences Institute, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Advanced Neurosciences Institute has several departments that took part in Clinical trials: "Advanced Neuroscience Center-Site Number:8400035" - 3 trials